PerkinElmer, Inc.
About PerkinElmer, Inc.
719 articles with PerkinElmer, Inc.
-
PerkinElmer Updates Second Quarter Outlook; To Hold Earnings Call on Tuesday, July 28, 2020
7/13/2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that it anticipates growth in both reported revenue and organic revenue1 of approximately 12% for the second quarter ended July 5, 2020.
-
PerkinElmer and American Society of Hematology Announce Global Collaboration to Help Combat Sickle Cell Disease
6/18/2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced a collaboration with the American Society of Hematology (ASH), the world's largest professional society of hematologists, to support a new effort to increase capacity for newborn screening, education, and cli
-
PerkinElmer Launches Pre-eclampsia Kit for Enhanced Management
6/10/2020
Addition of sFlt-1 for second and third trimester pre-eclampsia management rounds out portfolio
-
PerkinElmer to Present at Jefferies Global Healthcare Conference
5/20/2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the (virtual) Jefferies Global Healthcare Conference on Thursday, June 4, 2020 at 9:00 a.m. ET.
-
Official Statement from PerkinElmer in Response to Reuters Article Published on May 18, 2020
5/18/2020
PerkinElmer, Inc. (NYSE: PKI) supports government efforts to identify and prevent abusive practices in healthcare. PerkinElmer has received subpoenas from the government regarding investigations into third parties, and has fully cooperated with authorities and will continue to do so.
-
PerkinElmer Receives AOAC INTERNATIONAL First Action Official Methods of Analysis (OMA) Status for Solus One Salmonella Assay
5/11/2020
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, today announced its Solus One™ Salmonella assay and methods have been granted First Action Official Methods of Analysis℠ (OMA) status, number 2020.03, from AOAC INTERNATIONAL (Association of Official Analytical Collaboration).
-
FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies
5/5/2020
FDA Provides Emergency Use Authorization to PerkinElmer for Serological Test to Identify COVID-19 Antibodies
-
PerkinElmer Announces Financial Results for the First Quarter of 2020
5/5/2020
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, reported financial results for the first quarter ended April 5, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for May 5, 2020.
-
PerkinElmer to Present at BofA Securities Virtual Healthcare Conference 2020
5/1/2020
PerkinElmer, Inc. (NYSE: PKI), a global leader committed to innovating for a healthier world, today announced that the Company will present at the annual BofA Securities Virtual Healthcare Conference 2020 on Thursday, May 14, 2020 at 8:20 a.m. ET.
-
PerkinElmer Board Declares Quarterly Dividend payable on August 7, 2020
4/30/2020
The Board of Directors of PerkinElmer, Inc., declared a regular quarterly dividend of $0.07 per share of common stock on April 30, 2020.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.
-
PerkinElmer Launches Solutions to Streamline Analysis for Labs in Pharmaceuticals, Semiconductors, Biomonitoring, Food and Materials
4/20/2020
Multi-Quadrupole ICP-MS, FT-IR and automation innovations provide testing and research performance, flexibility and ease of use
-
Notice of Change of Location of Annual Meeting of Shareholders of PerkinElmer to Be Held on April 28, 2020
4/14/2020
PerkinElmer, Inc. gave notice that in response to continued public health restrictions on in-person gatherings given the coronavirus/COVID-19 pandemic, the Board of Directors of PerkinElmer has determined to change the format of the company’s Annual Meeting of Shareholders scheduled for Tuesday, April 28, 2020, at 8:00 a.m. EST from in-person to virtual-only.
-
PerkinElmer to Hold Earnings Call on Tuesday, May 5, 2020
4/13/2020
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that on Tuesday, May 5, 2020, after market close, the Company will release first quarter 2020 results.
-
PerkinElmer is the 16th company to receive an EUA for COVID-19 testing.
-
A summary of daily biopharma industry news. Please check out stories that are trending on March 25, 2020.
-
FDA Provides Emergency Use Authorization to PerkinElmer for COVID-19 Testing
3/24/2020
PerkinElmer, Inc., a global leader committed to innovating for a healthier world, announced that the U.S. Food and Drug Administration has provided Emergency Use Authorization for the Company’s New Coronavirus RT-PCR test.
-
PerkinElmer First Quarter 2020 Financial Performance Update
3/9/2020
PerkinElmer, Inc. announced that it expects first quarter 2020 revenue and earnings per share, both on a GAAP and non-GAAP basis, to be below the Company’s previously communicated guidance.
-
PerkinElmer Elects Michel Vounatsos to its Board of Directors
3/2/2020
PerkinElmer, Inc. (NYSE:PKI), a global leader committed to innovating for a healthier world, today announced that Michel Vounatsos has been elected to its board of directors, effective March 1, 2020.